Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2012

Originalarbeiten

  • Von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Müller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin lymphoma: Final analysis of the GHSG HD14 trial. J Clin Oncol 30(9);20:907-13 (2012)
  • Simhadri VL, Hansen HP, Simhadri VR, Reiners KS, Bessler M, Engert A, Pogge von Strandmann E. A novel role for reciprocal CD30-CD30L signaling in the cross-tlk between natural killer and dendritic cells. Biol Chem 393:101-6 (2012)
  • Behringer K, Thielen I, Müller H, Görgen H, Eibl AD, Rosenbrock J, Halbsguth T, Eichenauer DA, Fuchs M, Reiners KS, Renno JH, van der Ven K, Kuehr M, von Wolff M, Diehl V, Engert A, Borchmann P. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin Lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 23(7):1818-25 (2012)
  • Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Zdenek K, Fuchs M, Hallek M, Kanz L, Doehner H, Doerken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Knebe M, Pfreundschu6h M, Stein H, Eich H, Müller R-P, Dietlein M, Borchmann P, Diehl V. Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin Lymphoma: An open-label, randomised phase 3 trial. The Lancet 379 (9828);May 12:1791-99 (2012)
  • Kremer AE, Dijk RV, Leckie P, Schaap FG, Kuiper EM, Mettang T, Reiners KS, Raap U, Buuren HR, Erpecum KJ, Davies NA, Rust C, Engert A, Jalan R, Elferink RP, Beuers U. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. Hepatology Oct;56(4):1391-400 (2012)
  • Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson B, de Vos S, Forero-Torres A, Moskowitz C, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Results of a pivotal phase II study of Brentuximab Vedotin (SGN-35) for patients with relapsed or refractory Hodgkin lymphoma.  J Clin Oncol 30(18);20:2183-89 (2012)
  • Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ,  Kirschbaum M, Johnston P, Gallagher J, Le Corre C, Shen A, Engert A. Panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous stem cell transplant: results of a phase II study. J Clin Oncol 30(18)20:2197-2203 (2012)
  • Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M. Written on behalf of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG). Fludarabine and cyclophosphamide in combination with alemtuzumab (FCCAM) in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Letter to the editor. Leukemia Dec;26(12):2549-52
  • Kriz J, Bangard C, Haverkamp U, Bongartz R, Baues C, Engert A, Müller RP, Eich HT. Quality control of involved field (IF)-radiotherapy for patients with early-stage Hodgkin’s lymphoma based on a central prospective review. Strahlenther Onkol 188:660-5 (2012)
  • Sasse S, Klimm B, Görgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, Koch O, Wilhelm M, Trenn G, Finke J, Müller RP, Diehl V, Eich HT, Borchmann P, Engert A. German Hodgkin Study Group (GHSG). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early- stage Hodgkin’s Lymhoma.  Ann Oncol Nov;23(11):2953-9 (2012)
  • Rothe A, Sasse S, Görgen H, Eichenauer DA, Lohri A, Jäger U, Bangard C, Böll B, von Bergwelt Baildon M, Theurich S, Borchmann P, Engert A. Brentuximab Vedotin for relapsed or refractory CD30-positive hematologic malignancies – the GHSG experience. Blood 16;120(7):1470-2 (2012)
  • Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C, for the German HIV-Related Lymphoma Study Group. Stage-adapted treatment of human immunodeficiency virus associated Hodgkin lymphoma: Results of a prospective multicenter study. J Clin Oncol Nov 20;30(33):4117-23 (2012)
  • Kriz J, Müller RP, Müller H, Engert A, Kobe C, Eich HT. “Large mediastinal tumor mass” as a prognostic factor in Hodgkin’s Lymphoma (HL): Is the definition on the basis of a chest radiograph in the era of computed tomography (CT) obsolete? Strahlenther Onkol 188(11):1020-1024 (2012)
  • Klimm B, Brillant C, Skoetz N, Müller H, Engert A, Borchmann P. Einfluss von onkologischen Behandlungszentren auf den Therapieerfolg beim Hodgkin Lymphom. Dtsch Arztebl Int 109(51-52):893-9 (2012)

Übersichtsarbeiten

  • Fuchs M, Naumann R, Engert A. Hodgkin-Lymphome Leitlinie. Onkopedia Leitlinien; Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO) Februar (2012)
  • Eichenauer D, Borchmann P, Engert A. Adolescents with Hodgkin lymphoma – old children or young adults? Leuk & Lymphoma July 53(7):1257-62 (2012)
  • Rancea M, Skoetz N, Monsef I, Hübel K, Engert A, Bauer K. Fourteenth biannual report of the Cochrane Haematological Malignancies Group – Focus on autologous stem cell transplantation in Haematological Malignancies. J Natl Cancer Inst July 18;104(14) (2012)
  • Borchmann P, Eichenauer D, Engert A. State of the Art in the Treatment of Hodgkin Lymphoma. Nat Rev Clin Oncol Aug 9:450-59 (2012)
  • Eichenauer D, Engert A. Advances in the treatment of Hodgkin lymphoma. Int J Hematol  96(5):535-43 (2012)
  • Von Tresckow B, Engert A. The emerging role of PET in Hodgkin Lymphoma patients receiving autologous stem cell transplant. Exp Rev Hematol Oct;5(5):483-6 (2012)
  • Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest 122(10):3439–3447 (2012)
  • Fuchs M, Greil R, Lohri A, Engert A. Hodgkin Lymphome. DGHO Leitlinie. Onkopedia Leitlinien Juli (2012)